CSTL vs. VCYT, ARDT, ADUS, PGNY, PACS, LFST, NHC, TDOC, GRAL, and VRDN
Should you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Veracyte (VCYT), Ardent Health (ARDT), Addus HomeCare (ADUS), Progyny (PGNY), PACS Group (PACS), LifeStance Health Group (LFST), National HealthCare (NHC), Teladoc Health (TDOC), GRAIL (GRAL), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry.
Castle Biosciences vs. Its Competitors
Castle Biosciences (NASDAQ:CSTL) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.
Veracyte has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
In the previous week, Veracyte had 3 more articles in the media than Castle Biosciences. MarketBeat recorded 10 mentions for Veracyte and 7 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.95 beat Veracyte's score of 0.71 indicating that Castle Biosciences is being referred to more favorably in the media.
Castle Biosciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.
92.6% of Castle Biosciences shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by insiders. Comparatively, 1.4% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Veracyte has a net margin of 7.13% compared to Castle Biosciences' net margin of -1.46%. Veracyte's return on equity of 6.14% beat Castle Biosciences' return on equity.
Castle Biosciences presently has a consensus price target of $37.00, indicating a potential upside of 126.72%. Veracyte has a consensus price target of $40.90, indicating a potential upside of 73.97%. Given Castle Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Castle Biosciences is more favorable than Veracyte.
Summary
Veracyte beats Castle Biosciences on 10 of the 15 factors compared between the two stocks.
Get Castle Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Castle Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CSTL) was last updated on 7/22/2025 by MarketBeat.com Staff
Free CSTL Stock Alerts